News

Patients with relapsed or refractory multiple myeloma experienced improved progression-free survival with idecabtagene vicleucel. Notably, cytokine release syndrome rates were high with this treatment.

Elranatamab, an investigational BCMA/CD3-targeted bispecific antibody, has received priority review status for patients with relapsed or refractory multiple myeloma.

Nurses should educate patients not only about screening guidelines, but about important cancer risks to help improve cancer prevention.

Fox Chase Cancer Center has achieved Magnet designation for nursing excellence from the American Nurses Credentialing Center (ANCC) for the sixth consecutive time.

AON celebrates its Board of Managers’ appointments and retirements.

Terri Pollack, DNP, APRN, FNP-C, PMHNP-BC, shares some of her top takeaways from the 2023 ASCO GI Cancers Symposium.

The FDA has granted avasopasem a priority review for severe oral mucositis in patients with head and neck cancer who are receiving radiotherapy.

Extended follow-up of the CheckMate 274 trial showed continued efficacy with nivolumab in patients with muscle-invasive urothelial cancer who had undergone radical resection.

Restricted diets are commonplace at many cancer centers, but there is no evidence that they reduce a patient’s risk of infection.

Updated findings from the KEYNOTE-146 trial support the use of lenvatinib/pembrolizumab in advanced endometrial cancer.

The median overall survival was 42.1 months with abiraterone plus olaparib and 34.7 months with abiraterone plus placebo in patients with metastatic castration-resistant prostate cancer.

Approximately 30% of patients remained on treatment with darolutamide for over 4 years, according to a long-term safety and tolerability updated from the ARAMIS rollover study.

At a median follow-up of 24.9 months, imaging-based progression-free survival was not reached among patients with metastatic castration-resistant prostate cancer who had received talazoparib plus enzalutamide.

Long-term data support a de-escalated dose of tamoxifen for certain women with breast intraepithelial neoplasia who are unable to receive the standard dose.

Frontline ponatinib plus reduced-intensity chemotherapy yielded a higher minimal residual disease-negative complete remission rate than imatinib in the phase 3 PhALLCON study.

Prior authorization costs clinicians time and money. Heading into 2023, prior authorization was listed as a top administrative challenge.

As treatment strategies for renal cell carcinoma shift to targeted therapies and immunotherapy, reassessing the quality of end-of-life care remains essential, according to investigators.

Nursing education should be viewed as a long-course endeavor rather than a sprint.

Triple-negative breast cancer often occurs in women younger than 40.

Three groups have combined efforts to create a Health Equity Report Card pilot program which will seek to address the sources of disparities in the cancer care system.

Being an oncology nurse means supporting the patient—even through social media engagement.

In an 8 to 5 vote, ODAC voted in support of launching 2 single-arm trials seeking to characterize the risk-benefit profile of dostarlimab for patients with dMMR/MSI-H locally advanced rectal cancer.

According to Fennec Pharmaceuticals, the National Comprehensive Cancer Network is updating it guidelines to recommend injections of sodium thiosulfate to reduce the risk of ototoxicity in pediatric patients receiving cisplatin.

Anna Skwira-Brown, APRN, AOCNP, highlights the value of taking a moment to pause before embarking on a serious conversation with a patient during end-of-life care.

Dostarlimab-gxly has been granted regular approval for the treatment of patients with dMMR endometrial cancer. The label comes with warnings for immune-mediated adverse effects.

The National Comprehensive Cancer Network has updated their guidelines to include neratinib for patients with HER2-negative metastatic breast cancer.

Patients with head and neck squamous cell carcinoma continued to displayed a survival benefit with pembrolizumab at a 4-year follow-up.

A study in the Oncology Nursing Forum highlights which factors are associated with positive psychology and symptom burden in colorectal cancer survivors.